Home › NDC Lookup › RxCUI directory › RxCUI 198159

Prochlorperazine 25 MG Rectal Suppository — RxCUI 198159

RxNorm drug concept · Semantic clinical drug
RxCUI 198159 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI198159
Official nameProchlorperazine 25 MG Rectal Suppository
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped5
Reported Medicaid activity (SDUD)6,799 prescriptions · 36 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Prochlorperazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Prochlorperazine is most commonly used to control severe nausea and vomiting. Depending on the form your doctor prescribed, it may also be used to treat schizophrenia. The tablet f...
  • What is prochlorperazine actually used for?
  • The most common ones are drowsiness, dizziness, blurred vision, and a drop in blood pressure when you stand up quickly. More serious — but less common — reactions include uncontrol...
  • What side effects should I watch out for?
📖 Read our full Prochlorperazine guide →

🕸️ Concept Web — How Prochlorperazine 25 MG Rectal Suppository Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Prochlorperazine 25 MG Rectal Suppository RxCUI 198159

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Prochlorperazine 8704
  2. Brand names 2

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Compazine 203546
    • Compro 285056
  3. Dose forms 8

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Prochlorperazine Rectal Suppository 373608
    • Prochlorperazine Rectal Product 1162282
    • Prochlorperazine Rectal Suppository [Compazine] 367533
    • Prochlorperazine Rectal Suppository [Compro] 367534
    • Compazine Rectal Product 1167415
    • Compro Rectal Product 1167428
    • Rectal Suppository 316978
    • Rectal Product 1151127
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Prochlorperazine 25 MG 316596
    • Prochlorperazine 25 MG Rectal Suppository [Compazine] 207639
    • Prochlorperazine 25 MG Rectal Suppository [Compro] 284254
    • Prochlorperazine 25 MG [Compazine] 544002
    • Prochlorperazine 25 MG [Compro] 574744

Showing up to 8 concepts per family — 16 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Prochlorperazine 25 MG SCDC · 316596
  • Prochlorperazine Rectal Suppository SCDF · 373608
  • Prochlorperazine Rectal Product SCDG · 1162282

Brand-Name Concepts

  • Prochlorperazine 25 MG Rectal Suppository [Compro] SBD · 284254
  • Prochlorperazine 25 MG Rectal Suppository [Compazine] SBD · 207639
  • Prochlorperazine 25 MG [Compazine] SBDC · 544002
  • Prochlorperazine 25 MG [Compro] SBDC · 574744
  • Prochlorperazine Rectal Suppository [Compazine] SBDF · 367533
  • Prochlorperazine Rectal Suppository [Compro] SBDF · 367534
  • Compazine Rectal Product SBDG · 1167415
  • Compro Rectal Product SBDG · 1167428
  • Compazine BN · 203546
  • Compro BN · 285056

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 198159 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00574-7226-12 12 PACKET in 1 CARTON (0574-7226-12) / 1 SUPPOSITORY in 1 P... Compro Padagis US LLC 2000-09-01
00713-0135-10 1000 BLISTER PACK in 1 CARTON (0713-0135-10) / 1 SUPPOSITOR... Prochlorperazine Cosette Pharmaceuticals, Inc. 1993-11-30
00713-0135-12 12 BLISTER PACK in 1 CARTON (0713-0135-12) / 1 SUPPOSITORY... Prochlorperazine Cosette Pharmaceuticals, Inc. 1993-11-30
55289-0119-02 2 SUPPOSITORY in 1 BOTTLE, PLASTIC (55289-119-02) Compro PD-Rx Pharmaceuticals, Inc. 2010-12-22
55289-0119-06 6 SUPPOSITORY in 1 BOTTLE, PLASTIC (55289-119-06) Compro PD-Rx Pharmaceuticals, Inc. 2023-01-18
Observed labelers: Cosette Pharmaceuticals, Inc. (2) · PD-Rx Pharmaceuticals, Inc. (2) · Padagis US LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$4.9418
Range $4.9418–$6.3982 · middle 50% $4.9418–$5.6700 · 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.